Physician profile
Ramy Medhat Sayed
NPI 1518398437
$15,351.81
in general payments reported to CMS, 2019-2025
66 companies · $4,765 in 2025
The $4,765 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $983 · 2021: $987 · 2022: $1,614 · 2023: $2,543 · 2024: $3,578 · 2025: $4,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,840.56 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,850.71 | 2019-2025 | Wegovy, Ozempic, Saxenda |
| Astrazeneca Pharmaceuticals Lp | $1,193.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,162.28 | 2020-2025 | Vraylar, Linzess, Qulipta |
| Lilly USA, LLC | $814.78 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $732.63 | 2024-2025 | Evenity, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $684.74 | 2022-2025 | |
| Pfizer INC. | $621.38 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $598.10 | 2022-2025 | Rexulti |
| Esperion Therapeutics, INC. | $590.56 | 2020-2025 | Nexletol |
| Cequr Corporation | $518.17 | 2023-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $498.27 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $492.32 | 2019-2025 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $489.22 | 2019-2025 | Jardiance, Synjardy, Jascayd |
| Glaxosmithkline, LLC. | $465.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $336.96 | 2019-2025 | Xifaxan, Trulance, Cycloset |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $313.04 | 2023-2025 | Gemtesa |
| Lundbeck LLC | $302.33 | 2022-2025 | Rexulti, Vyepti |
| Axsome Therapeutics, INC. | $290.09 | 2023-2025 | Auvelity, Sunosi |
| Currax Pharmaceuticals LLC | $274.00 | 2021-2024 | Contrave, Nexletol, Nexlizet |
| Janssen Pharmaceuticals, INC | $273.87 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $261.20 | 2019-2023 | |
| Optinose US, INC. | $233.64 | 2025 | |
| Exact Sciences Corporation | $229.18 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $212.65 | 2020-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $194.20 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $155.54 | 2021-2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $121.57 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.36 | 2025 | Caplyta |
| Corcept Therapeutics | $102.70 | 2025 | Korlym |
| Ironwood Pharmaceuticals, INC | $86.39 | 2021-2024 | Linzess |
| Astellas Pharma US INC | $68.36 | 2024-2025 | Veozah |
| Intra-Sana Laboratories | $63.64 | 2023-2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Phathom Pharmaceuticals, INC. | $63.19 | 2024-2025 | Voquezna |
| Medtronic, INC. | $60.65 | 2023-2025 | Minimed 780g, Interstim |
| Amarin Pharma, INC. | $60.35 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $55.85 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $47.14 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $45.99 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.65 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $39.49 | 2020-2023 | Qelbree, Xyosted |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $36.73 | 2023 | Seglentis, Livalo |
| Azurity Pharmaceuticals, INC. | $36.48 | 2023-2025 | Edarbi, Alvesco |
| Alkermes, INC. | $34.33 | 2025 | Vivitrol |
| Endogastric Solutions, INC | $34.00 | 2022-2024 | Esophyx |
| Arbor Pharmaceuticals, INC. | $31.15 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $30.61 | 2025 | |
| Xeris Pharmaceuticals, INC. | $29.99 | 2022-2024 | Gvoke Hypopen |
| Verona Pharma, INC. | $24.34 | 2025 | Ohtuvayre |
| Phadia US INC. | $23.95 | 2024 | Immunocap |
| Mylan Specialty L.P. | $22.58 | 2024 | Yupelri |
| Boston Scientific Corporation | $21.44 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $20.30 | 2021 | |
| Ardelyx, INC. | $19.68 | 2024 | Ibsrela |
| Evoke Pharma, INC. | $19.57 | 2025 | |
| Corium, LLC | $18.85 | 2025 | Azstarys |
| Philips North America LLC | $18.30 | 2025 | Ecc Solutions |
| Hikma Pharmaceuticals USA | $17.37 | 2025 | Ryaltris |
| Insulet Corporation | $17.06 | 2022 | |
| Allergan, INC. | $15.56 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.76 | 2021 | |
| Halozyme INC | $14.50 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.72 | 2024 | Quviviq |
| Csl Behring | $13.70 | 2022 | |
| Zyla Life Sciences, INC. | $13.40 | 2019 | |
| Dermira, INC. | $11.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramy Sayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.